Gravity Evidence for a Larger Limpopo Belt in Southern Africa and Geodynamic Implications

The Limpopo Belt of southern Africa is a Neoarchean orogenic belt located between two older Archean provinces, the Zimbabwe craton to the north and the Kaapvaal craton to the south. Previous studies considered the Limpopo Belt to be a linearly trending east-northeast belt with a width of ∼250 km and ∼600 km long. We provide evidence from gravity data constrained by seismic and geochronologic data suggesting that the Limpopo Belt is much larger than previously assumed and includes the Shashe Belt in Botswana, thus defining a southward convex orogenic arc sandwiched between the two cratons. The 2 Ga Magondi orogenic belt truncates the Limpopo-Shahse Belt to the west. The northern marginal, central and southern marginal tectonic zones define a single gravity anomaly on upward continued maps, indicating that they had the same exhumation history. This interpretation requires a tectonic model involving convergence between the Kaapvaal and Zimbabwe cratons during a Neoarchean orogeny that preserved the thick cratonic keel that has been imaged in tomographic models

Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease

Epstein–Barr virus-positive post-transplant lymphoproliferative disease (PTLD) is a potentially lethal complication of iatrogenic immunosupression after transplantation. Predicting the development of PTLD allowing early and effective intervention is therefore of importance. Polymorphisms within cytokine genes are implicated in susceptibility to, and progression of, disease however the published data are often conflicting. We undertook investigation of polymorphic alleles within cytokine genes in PTLD and non-PTLD transplant cohorts to determine risk factors for disease. <br/> Methods: SSP-PCR was used to analyse single nucleotide polymorphism within tumour necrosis factor (TNF)-α, interleukin- 1, -6, -10 and lymphotoxin-α genes. The TNF-α levels were measured by standard enzyme-linked immuno-absorbant assay. <br/> Results: We show an association between variant alleles within the TNF-α promoter (−1031C (<i>P</i>=0.005)); −863A (<i>P</i>=0.0001) and TNF receptor I promoter regions (−201T (<i>P</i>=0.02)); −1135C (<i>P</i>=0.03) with the development of PTLD. We also show an association with TNF-α promoter haplotypes with haplotype-3 significantly increased (<i>P</i>=0.0001) and haplotype-1 decreased (P=0.02) in PTLD patients compared to transplant controls. Furthermore, we show a significant increase (<i>P</i>=0.02) in the level of TNF-α in PTLD patient plasma (range 0–97.97 pg ml<sup>−1</sup>) compared to transplant controls (0–8.147 pg ml<sup>−1</sup>), with the highest levels found in individuals carrying the variant alleles. <br/> Conclusion: We suggest that genetic variation within TNF-α loci and the level of plasma cytokine could be used as a predictive risk factor for the development of PTLD

Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy

Aims: Dilated cardiomyopathy (DCM) associated with dystrophin gene (DMD) mutations in individuals with mild or absent skeletal myopathy is often indistinguishable from other DCM forms. We sought to describe the phenotype and prognosis of DMD associated DCM in DMD mutation carriers without severe skeletal myopathy. Methods and results: At 26 European centres, we retrospectively collected clinical characteristics and outcomes of 223 DMD mutation carriers (83% male, 33 ± 15 years). A total of 112 individuals (52%) had DCM at first evaluation [n = 85; left ventricular ejection fraction (LVEF) 34 ± 11.2%] or developed DCM (n = 27; LVEF 41.3 ± 7.5%) after a median follow-up of 96 months (interquartile range 5–311 months). DCM penetrance was 45% in carriers older than 40 years. DCM appeared earlier in males and was independent of the type of mutation, presence of skeletal myopathy, or elevated serum creatine kinase levels. Major adverse cardiac events (MACE) occurred in 22% individuals with DCM, 18% developed end-stage heart failure and 9% sudden cardiac death or equivalent. Skeletal myopathy was not associated with survival free of MACE in patients with DCM. Decreased LVEF and increased left ventricular end-diastolic diameter at baseline were associated with MACE. Individuals without DCM had favourable prognosis without MACE or death during follow-up. Conclusions: DMD-associated DCM without severe skeletal myopathy is characterized by incomplete penetrance but high risk of MACE, including progression to end-stage heart failure and ventricular arrhythmias. DCM onset is the major determinant of prognosis with similar survival regardless of the presence of skeletal myopathy

Using hippocampal microRNA expression differences between mouse inbred strains to characterise miRNA function

Micro-RNAs (miRNAs) are short, single-stranded, noncoding RNAs that are involved in the regulation of protein-coding genes at the level of messenger RNA (mRNA). They are involved in the regulation of numerous traits, including developmental timing, apoptosis, immune function, and neuronal development. To better understand how the expression of the miRNAs themselves is regulated, we looked for miRNA expression differences among four mouse inbred strains, A/J, BALB/cJ, C57BL/6J, and DBA/2J, in one tissue, the hippocampus. A total of 166 miRNA RT-PCR assays were used to screen RNA pools for each strain. Twenty miRNA species that were markedly different between strains were further investigated using eight individual samples per strain, and 11 miRNAs showed significant differences across strains (p < 0.05). This is the first observation of miRNA expression differences across inbred mice strains. We conducted an in silico correlation analysis of the expression of these differentially expressed miRNAs with phenotype data and mRNA expression to better characterise the effects of these miRNAs on both phenotype and the regulation of mRNA expression. This approach has allowed us to nominate miRNAs that have potential roles in anxiety, exploration, and learning and memory

3D static and time-dependent modelling of a dc transferred arc twin torch system

International audienceThe transferred arc plasma torch device consists of two electrodes generating a plasma arc sustained by means of an electric current flowing through the body of the discharge. Modeling works investigating of transferred electric arc discharges generated between two suspended metallic electrodes, in the so called twin torch configuration, are scarce. The discharge generated by this particular plasma source configuration is characterized by a complex shape and fluid dynamics and needs a 3D description in order to be realistically predicted. The extended discharge length that goes from the tungsten pencil cathode to the flat copper anode without any particular confinement wall and the fluid dynamics and magnetic forces acting on the arc may induce an unsteady behavior. In order to capture the dynamic behavior of a twin torch discharge, a 3D time dependent plasma arc model has been developed using a customized commercial code FLUENT form in both Local Thermodynamic Equilibrium (LTE) and non-LTE. A two temperature (2T) model has been developed taking into account only the thermal non-equilibrium effects in argon plasma. The main differences between LTE and 2T models results concern the increased extension of the horizontal section of the discharge and the predicted reduced (of about 60-80V) voltage drop between the electrodes when using a 2T model

Two New Acylated Flavanone Glycosides from the Leaves and Branches of Phyllanthus emblica

Two new acylated flavanone glycosides, (S)-eriodictyol 7-O-(6″-O-trans-p-coumaroyl)-β-D-glucopyranoside (1) and (S)-eriodictyol 7-O-(6″-O-galloyl)-β-D-glucopyranoside (2) were isolated from the leaves and branches of Phyllanthus emblica together with a new phenolic glycoside, 2-(2-methylbutyryl)phloroglucinol 1-O-(6″-O-β-D-apiofuranosyl)-β-D-glucopyranoside (3), as well as 22 known compounds. Their structures were determined by spectral and chemical methods

BUILDING BRIDGES FOR INNOVATION IN AGEING : SYNERGIES BETWEEN ACTION GROUPS OF THE EIP ON AHA

The Strategic Implementation Plan of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) proposed six Action Groups. After almost three years of activity, many achievements have been obtained through commitments or collaborative work of the Action Groups. However, they have often worked in silos and, consequently, synergies between Action Groups have been proposed to strengthen the triple win of the EIP on AHA. The paper presents the methodology and current status of the Task Force on EIP on AHA synergies. Synergies are in line with the Action Groups' new Renovated Action Plan (2016-2018) to ensure that their future objectives are coherent and fully connected. The outcomes and impact of synergies are using the Monitoring and Assessment Framework for the EIP on AHA (MAFEIP). Eight proposals for synergies have been approved by the Task Force: Five cross-cutting synergies which can be used for all current and future synergies as they consider overarching domains (appropriate polypharmacy, citizen empowerment, teaching and coaching on AHA, deployment of synergies to EU regions, Responsible Research and Innovation), and three cross-cutting synergies focussing on current Action Group activities (falls, frailty, integrated care and chronic respiratory diseases).Peer reviewe